Detailed price information for Takeda Pharmaceutical Ltd ADR (TAK-N) from The Globe and Mail including charting and trades.

A multidrug regimen containing brentuximab vedotin (BV, Adcetris) proved feasible for older patients with advanced classical Hodgkin lymphoma (cHL), with outcomes similar to younger patients but with ...

Pfizer PFE is one of the biggest players in the oncology space — a position it strengthened with the 2023 acquisition of Seagen. The deal added four antibody-drug conjugates (ADC) — Adcetris, Padcev, ...

ADCETRIS (brentuximab vedotin) Important Safety Information (European Union) Please refer to Summary of Product Characteristics (SmPC) before prescribing.

OSAKA, Japan & CAMBRIDGE, Mass., June 03, 2025--Takeda (TSE:4502/NYSE:TAK) today announced that the European Commission (EC) approved ADCETRIS® (brentuximab vedotin) in combination with etoposide, ...

The approval for this ADCETRIS-based combination regimen, known as BrECADD, in frontline Hodgkin lymphoma is based on the results of the randomized Phase 3 HD21 trial. The study met its co-primary ...

Takeda has received a new recommendation from the European Medicines Agency’s human medicines committee for its Pfizer-partnered blood cancer drug Adcetris (brentuximab vedotin). The Committee for ...

Pfizer’s Adcetris combination regimen gets US FDA approval to treat relapsed/refractory diffuse large B-cell lymphoma New York Friday, February 14, 2025, 11:00 Hrs [IST] Pfizer Inc. announced that the ...

Approval of Adcetris provides a new treatment option for patients with relapsed or refractory large b-cell lymphoma who are ineligible for autologous stem cell transplantation.

ADCETRIS now provides a non-chemotherapy option for these patients, who are ineligible for autologous hematopoietic stem cell transplantation or CAR-T cell therapy.

"Today’s approval further reinforces the important role of ADCETRIS as an existing standard of care with overall survival improvement shown for certain types of lymphomas, and now allows ...